ENLIE Pharmaceutical JSC
UUPCOM:BCP8,500.00
VND
+500.00
(+6.25%)
ISIN
VN000000BCP6
Return %
Stock
S&P 500
1Y
-22.73
14.20
3Y
-11.46
81.12
5Y
-26.72
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Semi-annual Revenue
FRC
•
in mil. unless spec.Semi-annual Earnings Per Share
FRC
•
in mil. unless spec.Semi-annual Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Hung Manh An
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Binh Duong Vietnam
- IPO Date
- Sep 14, 2015
- Website
- enlie.vn
- Similar Companies
- Business
- ENLIE Pharmaceutical Joint Stock Company is a Vietnam-based pharmaceutical and healthcare manufacturing company engaged in the research, formulation, manufacturing, commercialization, and contract processing of pharmaceutical drugs, health supplements, medical equipment, and personal care products. Founded in 2007 and formerly known as Becamex Pharmaceutical Joint Stock Company before its corporate rebranding in 2019, the company is headquartered in Ben Cat City, Binh Duong Province, Vietnam, where it operates an industrial manufacturing complex certified under World Health Organization Good Manufacturing Practice (WHO-GMP), ISO 9001:2015, and ISO 13485:2016 standards. The company operates across multiple healthcare sectors, offering a diversified portfolio of products and services that comprises: prescription and over-the-counter pharmaceuticals spanning analgesics, antipyretics, and anti-inflammatory agents; antimicrobial and antibiotic drugs; cardiovascular and metabolic therapies; gastrointestinal, digestive, and antidiarrheal treatments such as Diosmectit Enlie; respiratory, antiallergic, and antitussive preparations; hepatobiliary and liver support medications; central nervous system agents and psychiatric therapies such as Diropam; dietary and nutritional supplements, including multivitamins, minerals, and functional health formulations; medical devices, consumables, and clinical healthcare supplies; dermatological preparations and cosmetic products; and contract manufacturing (OEM/ODM) and toll formulation services, providing third-party pharmaceutical partners with pilot batch manufacturing, analytical testing, regulatory dossier filing, tableting, capsule filling, and finished packaging. ENLIE Pharmaceutical distributes its therapeutic lines nationwide throughout Vietnam via institutional hospital bidding channels (ETC), clinic networks, pharmacy chains, and independent retail pharmacies (OTC). In recent operational and corporate developments, ENLIE Pharmaceutical has achieved a financial turnaround, returning to sustained operating profitability following multi-year structural adjustments. To strengthen its balance sheet and fund manufacturing optimizations, the company approved a private placement of 1.5 million equity shares to strategic investor Nam Phuong Pharmaceutical and Cosmetics Trading Company Limited, expanding its equity capital base toward VND 75 billion and retiring outstanding debt liabilities. In addition, the company has expanded its commercial portfolio through new domestic drug registration certificates granted by the Ministry of Health, including marketing authorizations for proprietary pharmaceutical formulations such as ENLIPITA, while enhancing its executive production leadership to expand contract manufacturing volume and improve operational plant throughput.